Press Releases

Date	Title and Summary	Additional Formats
Feb 10, 2020	Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Feb 10, 2020	Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™
Jan 20, 2020	Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System
Jan 14, 2020	Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019 Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM)
Jan 13, 2020	MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio Fluidigm microfluidics technology to fuel growth in genomics services SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MOgene, a leading provider of genomic and bioinformatic services in St. Louis , today announced it has selected Fluidigm’s (NASDAQ:FLDM) Advanta™ assays and
Dec 18, 2019	The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping SOUTH SAN FRANCISCO , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab , a hub for collaborative
Dec 12, 2019	Fluidigm Named to Greater Toronto's Top Employers for 2020 Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Canada, a subsidiary of Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
Dec 10, 2019	Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced
Dec 09, 2019	Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System 2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm SOUTH SAN FRANCISCO, Calif. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tools market, recognized Fluidigm (NASDAQ:FLDM) with the Gold Award for the
Nov 20, 2019	Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25%